Amparo Benito Berlinches-rekin lankidetzan egindako argitalpenak (12)

2024

  1. Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology

    Scientific Reports, Vol. 14, Núm. 1

  2. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

2022

  1. Identification of Trim24 as a new NTRK3 fusion partner in lung adenocarcinoma: Diagnostic challenges of a novel fusion

    Human Pathology Reports, Vol. 28

  2. Response to Mobocertinib in a patient with advanced Non-Small Cell Lung Cancer harboring EGFR exon 20 insertion after several therapies including Amivantamab

    Current Problems in Cancer: Case Reports, Vol. 5

2021

  1. ALK rearranged non–small cell lung carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors

    Current Problems in Cancer: Case Reports, Vol. 4

  2. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design

    Future Oncology, Vol. 17, Núm. 12, pp. 1459-1472

  3. Screening for ROS1 fusions in patients with advanced non-small cell lung carcinomas using the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody

    Expert Review of Molecular Diagnostics, Vol. 21, Núm. 5, pp. 437-444

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

  2. Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review

    Respiratory Medicine Case Reports, Vol. 26, pp. 310-314

  3. Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients

    Clinical Lung Cancer, Vol. 20, Núm. 4, pp. 305-312.e3

2018

  1. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781

2014

  1. Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

    PLoS ONE, Vol. 9, Núm. 9